Aspen Neuroscience, Inc. Form SCHEDULE 13D — Nov 6, 2026
OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC filed a Schedule 13D disclosing beneficial ownership of 3,589,132 shares of Aspen Neuroscience common stock, approximately 12.3% of the 29,078,600 shares outstanding following the company's IPO. The stake was built through OrbiMed Private Investments VII, LP across five preferred financing rounds from 2018 to September 2025, plus 1,000,000 shares purchased in the IPO at $15.00 per share; the preferred stock converted 1-for-9.8821 into common upon the IPO completion. The Reporting Persons state the position is for investment purposes only, with no plans to seek control or change management. However, OrbiMed member Peter A.
Key figures
- Shares Owned
- 3589132
- Lockup Days
- 180
- Percent Of Shares
- 12.3%
- Ipo Purchase Price
- $15.00 per share
- Ipo Purchase Shares
- 1000000
- Shares Outstanding Basis
- 29078600
- Preferred Conversion Ratio
- 1-for-9.8821
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.